Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2020
Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2020
SUMMARY
According to the recently published report 'Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2020'; Hepatitis C Virus Envelope Protein E2 pipeline Target constitutes close to 9 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.
Hepatitis C Virus Envelope Protein E2 - E2 is a viral structural protein found in the hepatitis C virus. It is present on the viral membrane and functions as a host receptor binding protein mediating entry into host cells. It is an important target for the design of entry inhibitors and vaccine immunogens.
The report 'Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2020' outlays comprehensive information on the Hepatitis C Virus Envelope Protein E2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 3 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Hepatitis C.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2020'; Hepatitis C Virus Envelope Protein E2 pipeline Target constitutes close to 9 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.
Hepatitis C Virus Envelope Protein E2 - E2 is a viral structural protein found in the hepatitis C virus. It is present on the viral membrane and functions as a host receptor binding protein mediating entry into host cells. It is an important target for the design of entry inhibitors and vaccine immunogens.
The report 'Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2020' outlays comprehensive information on the Hepatitis C Virus Envelope Protein E2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 3 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Hepatitis C.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Hepatitis C Virus Envelope Protein E2
- The report reviews Hepatitis C Virus Envelope Protein E2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics and enlists all their major and minor projects
- The report assesses Hepatitis C Virus Envelope Protein E2 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Hepatitis C Virus Envelope Protein E2 targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Hepatitis C Virus Envelope Protein E2Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatitis C Virus Envelope Protein E2 development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Hepatitis C Virus Envelope Protein E2 - Overview
Hepatitis C Virus Envelope Protein E2 - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Hepatitis C Virus Envelope Protein E2 - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatitis C Virus Envelope Protein E2 - Companies Involved in Therapeutics Development
Ennaid Therapeutics LLC
Integrated BioTherapeutics Inc
Toray Industries Inc
Hepatitis C Virus Envelope Protein E2 - Drug Profiles
CIGB-230 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis C (strain H77) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis C vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis C vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis C vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Hepatitis C - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit E1 and E2 Glycoprotein for Hepatitis C - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit E1 and E2 Glycoprotein for HCV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatitis C Virus Envelope Protein E2 - Dormant Products
Hepatitis C Virus Envelope Protein E2 - Discontinued Products
Hepatitis C Virus Envelope Protein E2 - Product Development Milestones
Featured News & Press Releases
Jun 10, 2013: IBT and Stanford Awarded STTR
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Hepatitis C Virus Envelope Protein E2 - Overview
Hepatitis C Virus Envelope Protein E2 - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Hepatitis C Virus Envelope Protein E2 - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatitis C Virus Envelope Protein E2 - Companies Involved in Therapeutics Development
Ennaid Therapeutics LLC
Integrated BioTherapeutics Inc
Toray Industries Inc
Hepatitis C Virus Envelope Protein E2 - Drug Profiles
CIGB-230 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis C (strain H77) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis C vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis C vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis C vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Hepatitis C - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit E1 and E2 Glycoprotein for Hepatitis C - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit E1 and E2 Glycoprotein for HCV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatitis C Virus Envelope Protein E2 - Dormant Products
Hepatitis C Virus Envelope Protein E2 - Discontinued Products
Hepatitis C Virus Envelope Protein E2 - Product Development Milestones
Featured News & Press Releases
Jun 10, 2013: IBT and Stanford Awarded STTR
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Ennaid Therapeutics LLC, H2 2020
Pipeline by Integrated BioTherapeutics Inc, H2 2020
Pipeline by Toray Industries Inc, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Ennaid Therapeutics LLC, H2 2020
Pipeline by Integrated BioTherapeutics Inc, H2 2020
Pipeline by Toray Industries Inc, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
